Cinfa Banks On ‘Multi-Layered’ Scientific Advice As It Files For EU Pegfilgrastim Biosimilar Review
Executive Summary
Cinfa Biotech is hoping that the advice it received from the EU regulators during the development of its pegfilgrastim biosimilar will help it succeed where others have failed.
You may also be interested in...
Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo
The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.
Four Biosimilar Pegfilgrastims Under EU Review After Sandoz Re-Submits Zioxtenzo
The EMA’s scientific committee, the CHMP, now has four biosimilar versions of Amgen’s neutropenia drug Neulasta (pegfilgrastim) under review, after Sandoz re-submitted its product at the end of October.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.